PLYX (Polaryx Therapeutics) Float Percentage Of Total Shares Outstanding: 43.28% (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLYX Polaryx Therapeutics Inc PLYX
13 GF Score
Price $2.26
View Full Analysis

What is Polaryx Therapeutics Float Percentage Of Total Shares Outstanding?

Polaryx Therapeutics PLYX +2.73% 13 Float Percentage Of Total Shares Outstanding is 43.28% as of Jul. 15, 2026. GuruFocus rates PLYX with a GF Score™ of 13/100.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Polaryx Therapeutics's float shares is 21.57 Mil. Polaryx Therapeutics's total shares outstanding is 49.85 Mil. Polaryx Therapeutics's float percentage of total shares outstanding is 43.28%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Polaryx Therapeutics's Insider Ownership is 1.71%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Polaryx Therapeutics's Institutional Ownership is 4.79%.

PLYX
13GF Score
Polaryx Therapeutics Inc PLYX
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polaryx Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Polaryx Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=21.57/49.85
=43.28%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 43.28% mean?
Polaryx Therapeutics (PLYX) has a Float Percentage Of Total Shares Outstanding of 43.28% as of Jul. 15, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Polaryx Therapeutics and its competitors.
Is Polaryx Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Polaryx Therapeutics' current Float Percentage Of Total Shares Outstanding is 43.28%. Overall, Polaryx Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Polaryx Therapeutics' Float Percentage Of Total Shares Outstanding compare to GUTS and NTHI?
Polaryx Therapeutics' Float Percentage Of Total Shares Outstanding of 43.28% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Polaryx Therapeutics and its competitors. Polaryx Therapeutics's current Float Percentage Of Total Shares Outstanding is 43.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaryx Therapeutics stock overvalued right now?
Polaryx Therapeutics (PLYX) has a current Float Percentage Of Total Shares Outstanding of 43.28%. The current Float Percentage Of Total Shares Outstanding is 43.28%. Polaryx Therapeutics' overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Polaryx Therapeutics (PLYX), the current Float Percentage Of Total Shares Outstanding is 43.28% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Polaryx Therapeutics Business Description

Address South Tower, 140 East Ridgewood Avenue, Suite 415, Paramus, NJ, USA, 07652
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
13GF Score

Get the complete analysis for PLYX

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.26
Price